Lazertinib is a 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), pending approval from a recognised stringent registration (SRA) authority, presenting superiority over the 1st generation of EGFR TKI. Lazertinib has a strong potential as alternative option for lung cancer treatment.